Clinical Trial Update: A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

AK104 is in a Phase II trial for advanced non-small cell lung cancer, with the study status listed as active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Akeso | Conditions: Advanced Non-small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING